Puma Biotechnology, Inc. (PBYI) - Debt to Equity

Demand for Puma Biotechnology (PBYI) oncology drugs is completely independent of economic cycles or seasonality, demonstrating resilience to any shocks. This price chart on GURU.Markets shows a debt-to-equity ratio of 0.03, underscoring the company's role in the therapy of HER2-positive forms of cancer. However, stagnant growth of the core product and rising promotion costs limit further business expansion.

Puma Bio - PBYI Debt to Capital (period 07/04/2022 - 10/27/2026)

Analytical breakdowns for Puma Biotechnology

- price and consensus price forecast:

Stock Price Puma Bio|PBYI - Price Target Chart

- market capitalization data:

Market Value Puma Biotechnology|PBYI - Value Adjusted for Debt and Cash

- book capitalization data:

Book Value per Share Puma Biotechnology|PBYI - Total Stockholders' Equity|Market Capitalization to Book Value Ratio pumabiotechnology.com|PBYI - Company Total Assets

- debt and liquidity data:

Debt to Equity Puma Biotechnology|PBYI - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Puma Bio|PBYI - Company Cumulative Indebtedness|Debt to Book Value Puma Biotechnology

Comprehensive company analysis:PBYI - Puma Biotechnology

Flagship merchandise of Puma Biotechnology Inc

Analyzing the financial leverage dynamics of Puma Biotechnology (PBYI), one can assess the stability of this biotech issuer. This ratio compares total liabilities to net asset value, determining the degree of dependence on borrowed funds. An increase in this metric signals a rising debt load and a risk of liquidity loss. Given the independent product cycle of Puma Biotechnology, this indicator confirms the business's defensive status. Low leverage guarantees the stable development of innovative research.

Main competitors